| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | DGX | Common Stock | Award | $1.47M | +9.92K | +14.62% | $147.86 | 77.7K | Mar 6, 2023 | Direct | F1 |
| transaction | DGX | Common Stock | Tax liability | -$682K | -4.61K | -5.93% | $147.86 | 73.1K | Mar 6, 2023 | Direct | F2 |
| transaction | DGX | Common Stock | Sale | -$746K | -5.31K | -7.26% | $140.55 | 67.8K | Mar 7, 2023 | Direct | F3 |
| holding | DGX | Common Stock | 4.25K | Mar 6, 2023 | 401(k)/SDCP | F4 |
| Id | Content |
|---|---|
| F1 | Stock issued by Quest Diagnostics Incorporated in settlement of a performance share award dated February 18, 2020, approved in accordance with the requirements of Rule 16b-3(d). |
| F2 | Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance share award. |
| F3 | The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on October 27, 2022. |
| F4 | These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) and/or Supplemental Deferred Compensation Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under each Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date. |